Literature DB >> 15888489

Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Chee Yeun Chung1, Hyemyung Seo, Kai Christian Sonntag, Andrew Brooks, Ling Lin, Ole Isacson.   

Abstract

Molecular differences between dopamine (DA) neurons may explain why the mesostriatal DA neurons in the A9 region preferentially degenerate in Parkinson's disease (PD) and toxic models, whereas the adjacent A10 region mesolimbic and mesocortical DA neurons are relatively spared. To characterize innate physiological differences between A9 and A10 DA neurons, we determined gene expression profiles in these neurons in the adult mouse by laser capture microdissection, microarray analysis and real-time PCR. We found 42 genes relatively elevated in A9 DA neurons, whereas 61 genes were elevated in A10 DA neurons [> 2-fold; false discovery rate (FDR) < 1%]. Genes of interest for further functional analysis were selected by criteria of (i) fold differences in gene expression, (ii) real-time PCR validation and (iii) potential roles in neurotoxic or protective biochemical pathways. Three A9-elevated molecules [G-protein coupled inwardly rectifying K channel 2 (GIRK2), adenine nucleotide translocator 2 (ANT-2) and the growth factor IGF-1] and three A10-elevated peptides (GRP, CGRP and PACAP) were further examined in both alpha-synuclein overexpressing PC12 (PC12-alphaSyn) cells and rat primary ventral mesencephalic (VM) cultures exposed to MPP+ neurotoxicity. GIRK2-positive DA neurons were more vulnerable to MPP+ toxicity and overexpression of GIRK2 increased the vulnerability of PC12-alphaSyn cells to the toxin. Blocking of ANT decreased vulnerability to MPP+ in both cell culture systems. Exposing cells to IGF-1, GRP and PACAP decreased vulnerability of both cell types to MPP+, whereas CGRP protected PC12-alphaSyn cells but not primary VM DA neurons. These results indicate that certain differentially expressed molecules in A9 and A10 DA neurons may play key roles in their relative vulnerability to toxins and PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888489      PMCID: PMC2674782          DOI: 10.1093/hmg/ddi178

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  91 in total

Review 1.  Complex I and Parkinson's disease.

Authors:  J T Greenamyre; T B Sherer; R Betarbet; A V Panov
Journal:  IUBMB Life       Date:  2001 Sep-Nov       Impact factor: 3.885

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain.

Authors:  Henrike Neuhoff; Axel Neu; Birgit Liss; Jochen Roeper
Journal:  J Neurosci       Date:  2002-02-15       Impact factor: 6.167

4.  Global functional profiling of gene expression.

Authors:  Sorin Draghici; Purvesh Khatri; Rui P Martins; G Charles Ostermeier; Stephen A Krawetz
Journal:  Genomics       Date:  2003-02       Impact factor: 5.736

Review 5.  Normal values of insulin-like growth factor I and their clinical utility in adults.

Authors:  C J Strasburger; M Bidlingmaier; Z Wu; K M Morrison
Journal:  Horm Res       Date:  2001

6.  Effects of age and insulin-like growth factor-1 on neuron and synapse numbers in area CA3 of hippocampus.

Authors:  B H Poe; C Linville; D R Riddle; W E Sonntag; J K Brunso-Bechtold
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 7.  Rab GTPases, intracellular traffic and disease.

Authors:  Miguel C Seabra; Emilie H Mules; Alistair N Hume
Journal:  Trends Mol Med       Date:  2002-01       Impact factor: 11.951

8.  Insulin-like growth factor-1 improves somatosensory function and reduces the extent of cortical infarction and ongoing neuronal loss after hypoxia-ischemia in rats.

Authors:  J Guan; O T Miller; K M Waugh; D C McCarthy; P D Gluckman
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

9.  Differential expression of the small-conductance, calcium-activated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons.

Authors:  J Wolfart; H Neuhoff; O Franz; J Roeper
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

10.  Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.

Authors:  Vincenzo Bonifati; Patrizia Rizzu; Marijke J van Baren; Onno Schaap; Guido J Breedveld; Elmar Krieger; Marieke C J Dekker; Ferdinando Squitieri; Pablo Ibanez; Marijke Joosse; Jeroen W van Dongen; Nicola Vanacore; John C van Swieten; Alexis Brice; Giuseppe Meco; Cornelia M van Duijn; Ben A Oostra; Peter Heutink
Journal:  Science       Date:  2002-11-21       Impact factor: 47.728

View more
  156 in total

Review 1.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

2.  Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain.

Authors:  Sara L Montgomery; Michael A Mastrangelo; Diala Habib; Wade C Narrow; Sara A Knowlden; Terry W Wright; William J Bowers
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

3.  Human dopamine transporter gene: differential regulation of 18-kb haplotypes.

Authors:  Ying Zhao; Nian Xiong; Yang Liu; Yanhong Zhou; Nuomin Li; Hong Qing; Zhicheng Lin
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

4.  An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease.

Authors:  Chee Yeun Chung; James B Koprich; Shogo Endo; Ole Isacson
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

Review 5.  Strategies to unravel molecular codes essential for the development of meso-diencephalic dopaminergic neurons.

Authors:  F M J Jacobs; S M Smits; K J M Hornman; J P H Burbach; M P Smidt
Journal:  J Physiol       Date:  2006-06-29       Impact factor: 5.182

Review 6.  Reverse genetics for proteomics: from proteomic discovery to scientific content.

Authors:  M Bauer; M Ueffing
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

Review 7.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

8.  miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling.

Authors:  Woori Kim; Yenarae Lee; Noah D McKenna; Ming Yi; Filip Simunovic; Yulei Wang; Benjamin Kong; Robert J Rooney; Hyemyung Seo; Robert M Stephens; Kai C Sonntag
Journal:  Neurobiol Aging       Date:  2014-01-24       Impact factor: 4.673

9.  Loss of PINK1 attenuates HIF-1α induction by preventing 4E-BP1-dependent switch in protein translation under hypoxia.

Authors:  William Lin; Natasha L Wadlington; Linan Chen; Xiaoxi Zhuang; James R Brorson; Un Jung Kang
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

10.  Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.

Authors:  Chee Yeun Chung; James B Koprich; Penelope J Hallett; Ole Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.